Fitzgerald Kevin Joseph

Kevin Joseph Fitzgerald (CSO, EVP) sold 3,250 shares at $323.62 avg for $1.1M on Mar 2-3; stock down 29.7% in 90 days

Kevin Joseph Fitzgerald, Chief Strategy Officer and EVP Head of Research, executed 14 separate sales totaling 3,250 shares for $1,051,773.01 across March 2-3, 2026, reducing his holdings by 12.9% from 25.1K to 21.9K shares. The multi-day execution at prices ranging from $316.55 to $332.64 represents a significant liquidation by a senior research executive. The stock has declined 29.7% over the 90-day period and currently trades at $327.30, 33.4% below its 52-week high of $491.22, suggesting the company has faced material adverse movement since these sales. His prior five trades at ALNY show negative 30-day returns ranging from 16.6% to 17.3%, though 90-day outcomes remain incomplete for the most recent sales prior to this filing.

CSO Kevin Joseph Fitzgerald sells 4,000 ALNY shares in 2 transactions ($607,448.29 + $677,531.58); stock down -7.4% in 30 days, -27.8% in 90 days.

Kevin Joseph Fitzgerald, CSO & EVP Head of Research at Alnylam, executed 2 separate sales totaling 4,000 shares for $1,284,979.87 across two trading days (2026-02-13 and 2026-02-17) at blended average price $321.24, reducing holdings from 25.3K to 21.3K shares (-15.8%). The stock has declined -7.4% over 30 days and -27.8% over 90 days from current price $332.61, and is now trading -32.3% from its 52-week high of $491.22. His prior 5 sales at ALNY on 2026-01-13 each showed negative 30-day returns (-16.4% to -17.3%), establishing a pattern of sales preceding near-term weakness. This selling activity in a stock with strong fundamentals (revenue $1.2B, net income $251.1M, +65.2% annual growth) and elevated valuation (P/E 69.44) occurs as the stock faces sustained downward pressure, warranting investor attention to whether this represents conviction-based liquidation or routine portfolio management.

CSO/EVP Kevin Fitzgerald sold 3,800 shares ($1.4M) over 2 days at ALNY; holdings now 21,264 shares post-transaction.

Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, executed 27 separate sales totaling 3,800 shares for $1,395,992.00 across January 12–13, 2026, reducing holdings from 25,064 shares to 21,264 shares (a 15.2% reduction). The blended average sale price of $367.37 sits near current price of $366.86, but the stock is -25.3% from its 52-week high and down 6.3% over the past 30 days and 23.7% over 90 days. Notably, Fitzgerald's cross-ticker track record shows a 100.00% well-timed rate on 20 prior sells with average 90-day returns of -12.2%, suggesting a strong historical pattern of selling before declines; however, his five recent ALNY sales in November 2025 showed mixed 30-day outcomes (-12.7% to -15.3%) with no measurable 90-day results yet. The company reported net income of $251,084,000.00 last quarter against $1,249,026,000.00 revenue (+23.0% annual growth), yet carried negative full-year net income, creating a disconnect between recent profitability and historical losses that warrants monitoring alongside this substantial reduction in insider holdings.

CSO/EVP Kevin Joseph Fitzgerald sells 12,128 shares for $5,483,989.61; post-sale holdings 21,264 shares (36.3% reduction).

Kevin Joseph Fitzgerald, CSO and Head of Research at Alnylam Pharmaceuticals, executed 11 separate sales on 2025-11-17 totaling 12,128 shares (12.1K shares) for $5,483,989.61 ($5.5M) at prices ranging from $449.00 to $461.96 with a blended average price of $452.18, reducing his holdings by 36.3% from 33,392 shares to 21,264 shares. The stock is currently trading at $460.76, which is 6.2% below its 52-week high of $491.22. Across his prior open-market activity at this ticker, Fitzgerald has executed 5 additional sells in early October 2025, with 30-day returns ranging from -0.4% to +2.1%; however, no measurable 90-day outcomes are yet available for those trades. His broader cross-ticker track record shows 20 prior sells with an 87.50% well-timed rate at the 90-day mark, indicating a historical pattern of selling before price declines. The company's fundamentals show strong revenue growth of +23.0% year-over-year with $1.2B in latest quarterly revenue and $251.1M in net income, though it was unprofitable over its most recent full fiscal year, and the P/E ratio of 1396.24 reflects a significant valuation premium.

CSO Kevin Fitzgerald sold 2,441 shares at blended $452.05 (totaling $1.1M) on 2025-10-02; retains 25,231 shares

Fitzgerald executed 12 separate sales on a single day totaling 2,441 shares for $1,103,451.46, reducing his position by 8.8% from 27,672 to 25,231 shares. The stock has appreciated 2.0% over the prior 30 days and 37.5% over 90 days, trading 5.4% below its 52-week high of $482.13. Across his cross-ticker trade history, Fitzgerald's prior 20 sales averaged +5.2% 30-day returns and +25.1% 90-day returns with a well-timed rate of 0.00%, indicating his prior sales have not captured downside timing; his 5 prior same-ticker sales at ALNY all showed minimal near-term price movement (ranging -0.5% to +0.4% over 30 days). Alnym remains unprofitable (full-year net income negative) despite strong revenue growth of 23.0% year-over-year and a market cap of $59.8B, a fundamental backdrop consistent with high volatility and valuation risk in growth-stage biotech.

Alnylam CSO Kevin Fitzgerald sold 1,396 shares for $632,758.71 across 8 transactions on 2025-08-18; stock now at 52-week high.

Kevin Fitzgerald, CSO & EVP Head of Research at Alnylam, executed 8 separate sales totaling 1,396 shares for $632,758.71 on 2025-08-18 at blended average price $453.27. The transaction occurred with the stock trading at its 52-week high of $458.28 (+0.0% from the high), following a 30-day gain of +43.0% and 90-day gain of +56.6%. Fitzgerald retained 22,719 shares post-sale, a -5.8% reduction from his pre-transaction holdings of 24,115 shares. His prior sales at Alnylam (5 trades in 2025-03) showed subsequent positive returns at the 90-day mark (ranging +25.2% to +27.9%), with 0 of 5 prior sales at this ticker achieving well-timed exits. The company is unprofitable (net income $-66,277,000.00 in the latest quarter) despite strong revenue growth of +23.0% annually.

Fitzgerald (CSO & EVP, Research) sold 2,755 shares across 14 transactions for $669,304.07 on March 3–4, 2025.

Fitzgerald executed 14 separate sales totaling 2,755 shares for $669,304.07 at a blended average price of $242.94 over two trading days (March 3–4, 2025), reducing his holdings by 16.9% from 16,256 to 13,501 shares. The current stock price is $249.23, meaning he sold at a slight discount to today's market; the stock is down 9.2% over the prior 30 days and down 1.0% over 90 days. His cross-ticker track record shows a 100.00% well-timed rate on prior sells with an average 90-day return of -2.7%, but this is his first measurable trade at ALNY since five sales on 2025-02-18 (outcomes not yet measurable). The company reported positive revenue growth of 23.0% year-over-year but remains unprofitable with net income of $-111,570,000.00 on quarterly revenue of $500,919,000.00, warranting close attention to whether sustained profitability follows.

CSO Kevin Joseph Fitzgerald sold 2,103 shares at blended avg $252.71 on Feb 14–18, reducing stake 14.0% to 12,881 shares.

Kevin Joseph Fitzgerald, CSO & EVP Head of Research at Alnylam Pharmaceuticals, executed 17 separate sales totaling 2,103 shares for $531,447.79 across February 14–18, 2025, at prices ranging from $250.21 to $264.87. His post-transaction holdings of 12,881 shares represent a 14.0% reduction from the pre-transaction level of 14,984 shares. At the current price of $250.00, the stock trades 16.8% below its 52-week high of $300.55, though it has gained 1.5% over the past 30 days. Alnylam remains unprofitable with a net income of $-111.6M on quarterly revenue of $500.9M, though annual revenue growth stands at 23.0%. Fitzgerald's prior sales at this ticker (November 2024) each yielded negative 30-day returns ranging from −2.8% to −6.5%, though 90-day outcomes remain unmeasurable; his cross-ticker track record shows a 0.00% well-timed sell rate over 15 prior sales with an average 90-day return of +2.1% post-sale.

CSO Kevin Fitzgerald sells 3,000 shares at blended average $251.65 for $754.9K; stock down 11.6% in 30-day period.

Kevin Fitzgerald, Chief Strategy Officer & EVP of Research, executed 9 separate sales totaling 3,000 shares over November 26-27, 2024, netting $754,946.54 at a blended average price of $251.65. This represents an 18.9% reduction in his holdings (from 15,881 to 12,881 shares). The filing occurs against a backdrop of stock weakness: ALNY has declined 11.6% over the past 30 days and trades 15.6% below its 52-week high of $300.55. Fitzgerald's prior sales at ALNY show a consistent pattern of poor timing: across 5 prior trades at this ticker, 0 of 5 were well-timed by the 90-day mark (all saw the stock rise after his exits). His cross-ticker track record shows an identical 0.00% 90-day well-timed rate. While the company grew revenue 76.2% year-over-year and currently trades near recent highs, it remains unprofitable at the full-year level ($-111.6M net income in the latest fiscal year). The timing and scale of this liquidation in a declining-price environment, coupled with the insider's consistent inability to catch downturns in prior ALNY trades, warrants investor attention to underlying business trajectory and any near-term catalysts.

CSO Kevin Fitzgerald sells 22,025 shares at $268.66–$274.65 for $5,968,515.60; reduces stake by 63.1%

Kevin Joseph Fitzgerald, CSO & EVP Head of Research at Alnylam Pharmaceuticals, executed 6 separate sales totaling 22,025 shares for $5,968,515.60 on 2024-08-12 at prices ranging from $268.66 to $274.65 (blended average $270.99). This sale reduced his holdings from 34,906 shares to 12,881 shares, a 63.1% reduction in his position. The stock is trading at $262.89 currently, down 3.4% from its 52-week high of $272.05, though it remains up 73.8% over the past 90 days. Alnylam is growing revenue aggressively at 76.2% year-over-year but remains unprofitable at the full-year level; the most recent quarterly net income was -$16.9M on revenue of $659.8M. A substantial reduction in holdings by a senior research executive at a growth-stage biotech company warrants investor scrutiny of both the individual's conviction and any broader operational signals.